All patients | Primary | Bone metastasis | Multifocal | Locally recurrent | Extraskeletal | LTFU | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
104 | 100 | 84 | 80.7 | 51 | 4.8 | 62 | 5.8 | 22 | 1.9 | 2 | 1.9 | 71 | 6.7 | |
Sex | ||||||||||||||
Male | 59 | 56.7 | 50 | 59.5 | 3 | 60 | 3 | 50 | 0 | 1 | 50 | 2 | 28.6 | |
Female | 45 | 43.2 | 34 | 40.5 | 21 | 40 | 32 | 50 | 22 | 100 | 1 | 50 | 51 | 71.4 |
Age (years) | ||||||||||||||
Mean | 18.1 | 17.5 | 17.8 | 29 | 19 | 18.5 | 15.7 | |||||||
Range | 2–53 | 2–53 | 12–26 | 12–45 | 12–24 | 15–22 | 9–26 | |||||||
Tumor size | ||||||||||||||
Mean (cm) | 8.8 | |||||||||||||
< 9 cm | 51 | 49 | 38 | 45.2 | 41 | 80 | 22 | 33.3 | 22 | 100 | 2 | 100 | 51 | 71.4 |
> 9 cm | 43 | 41.3 | 38 | 45.2 | 1 | 20 | 3 | 50 | 0 | 0 | 1 | 14.3 | ||
Unknown | 10 | 9.6 | 8 | 9.5 | 0 | 1 | 16.6 | 0 | 0 | 1 | 14.3 | |||
Tumor volume | ||||||||||||||
< 200 ml | 18 | 17.3 | ||||||||||||
> 200 ml | 35 | 33.6 | ||||||||||||
Unknown | 51 | 49 | ||||||||||||
Tumor location | ||||||||||||||
Upper posterior | 52 | 50 | 43 | 51.2 | 51 | 100 | 2 | 33.3 | 0 | 0 | 31 | 42.9 | ||
Lower anterior | 31 | 29.8 | 25 | 29.8 | 0 | 22 | 33.3 | 12 | 50 | 0 | 4 | 57.1 | ||
Periacetabular | 18 | 17.3 | 15 | 17.8 | 0 | 2 | 33.3 | 1 | 50 | 0 | 0 | |||
Gluteal | 2 | 1.9 | 0 | 0 | 0 | 0 | 2 | 100 | 0 | |||||
Unknown | 1 | 0.9 | 1 | 1.2 | 0 | 0 | 0 | 0 | 0 | |||||
Surgical procedure | ||||||||||||||
Internal intraarticular | 51 | 49 | 43 | 51.2 | 0 | 22 | 33.3 | 12 | 50 | 1 | 50 | 5 | 71.4 | |
Internal extraarticular | 13 | 12.5 | 9 | 10.7 | 0 | 2 | 33.3 | 1 | 50 | 1 | 50 | 0 | ||
Internal (without joint involvement) | 39 | 37.5 | 31 | 36.9 | 51 | 100 | 2 | 33.3 | 0 | 0 | 21 | 28.6 | ||
Hindquarter amputation | 1 | 0.9 | 1 | 1.2 | 0 | 0 | 0 | 0 | 0 | |||||
Resection type (Enneking) | ||||||||||||||
P1a | 3 | 2.9 | 0 | 31 | 60 | 0 | 0 | 0 | 11 | 14.3 | ||||
P1b | 1 | 0.9 | 0 | 1 | 20 | 0 | 0 | 0 | 0 | |||||
P1-2 | 2 | 1.9 | 2 | 2.4 | 0 | 0 | 0 | 0 | 0 | |||||
P1c | 31 | 29.8 | 27 | 32.1 | 1 | 20 | 2 | 33.3 | 0 | 0 | 1 | 14.3 | ||
P1c + HS | 2 | 1.9 | 2 | 2.4 | 0 | 0 | 0 | 0 | 0 | |||||
P1-2-3 | 2 | 1.9 | 2 | 2.4 | 0 | 0 | 0 | 0 | 0 | |||||
P1-2-4 | 14 | 13.5 | 11 | 13.1 | 0 | 0 | 0 | 2 | 100 | 1 | 14.3 | |||
P1-2-4 + HS | 2 | 1.9 | 2 | 2.4 | 0 | 0 | 0 | 0 | 0 | |||||
P1-2-3-4 | 15 | 14.4 | 12 | 14.3 | 0 | 2 | 33.3 | 1 | 50 | 0 | 0 | |||
P1-2-3-4 + HS | 1 | 0.9 | 1 | 1.2 | 0 | 0 | 0 | 0 | 0 | |||||
P2 | 1 | 0.9 | 0 | 0 | 0 | 0 | 0 | 1 | 14.3 | |||||
P2-3 | 14 | 13.5 | 12 | 14.3 | 0 | 12 | 16.6 | 12 | 50 | 0 | 1 | 14.3 | ||
P3 | 15 | 14.4 | 12 | 14.3 | 0 | 1 | 16.6 | 0 | 0 | 2 | 28.6 | |||
Unknown | 1 | 0.9 | 1 | 1.2 | 0 | 0 | 0 | 0 | 0 | |||||
Reconstruction types | ||||||||||||||
Hip transposition | 33 | 31.7 | ||||||||||||
Hip transposition w/proximal femur replacement | 9 | 8.7 | ||||||||||||
Hip transposition spacer | 2 | 1.9 | ||||||||||||
Pelvic implant | 1 | 0.9 | Combined with hip transposition, n = 1 | |||||||||||
Flail hip | 1 | 0.9 | Combined with hip transposition, n = 1 | |||||||||||
Screw-rod reconstruction w/bone cement sheath | 19 | 18.3 | ||||||||||||
Autologous iliac bone graft osteosynthesis | 6 | 5.8 | Combined with hip transposition, n = 1 | |||||||||||
Autologous fibula bone graft osteosynthesis | 5 | 4.8 | Combined with hip transposition, n = 1 | |||||||||||
Allograft osteosynthesis | 7 | 6.7 | ||||||||||||
Soft tissue reconstruction only | 21 | 20.2 | ||||||||||||
EWSR 1 translocation status | ||||||||||||||
Present | 62 | 59.6 | ||||||||||||
Absent | 2 | 1.9 | ||||||||||||
Unknown | 40 | 38.5 | ||||||||||||
Histologic response to neoadjuvant chemotherapy (Salzer-Kuntschik) | ||||||||||||||
1 (no vital tumor) | 54 | 51.9 | 46 | 54.8 | 51 | 100 | 1 | 16.6 | 0 | 0 | 31 | 42.9 | ||
2 (isolated cells) | 6 | 5.8 | 3 | 3.6 | 0 | 1 | 16.6 | 0 | 0 | 2 | 28.6 | |||
3 (< 10% viable cells) | 22 | 21.2 | 18 | 21.4 | 0 | 0 | 0 | 2 | 100 | 2 | 28.6 | |||
4 (10–50% viable cells) | 13 | 12.5 | 11 | 13.1 | 0 | 22 | 33.3 | 12 | 50 | 0 | 0 | |||
5 (> 50% viable cells) | 5 | 4.8 | 3 | 3.6 | 0 | 2 | 33.3 | 0 | 0 | 0 | ||||
6 (no response to chemo) | 1 | 0.9 | 0 | 0 | 0 | 1 | 50 | 0 | 0 | |||||
Unknown | 3 | 2.9 | 3 | 3.6 | 0 | 0 | 0 | 0 | 0 | |||||
Surgical margins | ||||||||||||||
R0 | 98 | 94.2 | 78 | 92.8 | 51 | 100 | 62 | 100 | 22 | 100 | 2 | 100 | 71 | 100 |
Planned R1 | 2 | 1.9 | 2 | 2.4 | 0 | 0 | 0 | 0 | 0 | |||||
Unplanned R1 | 2 | 1.9 | 2 | 2.4 | 0 | 0 | 0 | 0 | 0 | |||||
Unknown | 2 | 1.9 | 2 | 2.4 | 0 | 0 | 0 | 0 | 0 | |||||
Disease extent | ||||||||||||||
Localized | 34 | 32.7 | 34 | 40.5 | 0 | 0 | 0 | 0 | 0 | |||||
Metastatic at diagnosis | 45 | 43.3 | 30 | 35.7 | 51,3 | 100 | 62 | 100 | 22 | 100 | 2 | 100 | 21 | 28.6 |
Metastatic after pelvic resection | 17 | 16.3 | 17 | 20.2 | 0 | 0 | 0 | 0 | 0 | |||||
Unknown | 8 | 7.7 | 3 | 3.6 | 0 | 0 | 0 | 0 | 5 | 71.4 | ||||
Number of metastatic organ sites | ||||||||||||||
Single (one other organ system) | 22 | |||||||||||||
Multiple (> 1 other organ systems) | 7 | |||||||||||||
Local recurrence | ||||||||||||||
8 | 7.7 | 6 | 7.1 | 0 | 2 | 33.3 | 0 | 0 | 0 | |||||
Radiation | ||||||||||||||
Yes | 81 | 77.8 | ||||||||||||
Neoadjuvant | 17 | 16.3 | 14 | 16.6 | 0 | 22,4 | 33.3 | 22 | 100 | 0 | 0 | |||
Adjuvant | 53 | 51 | 46 | 54.8 | 3 | 60 | 1 | 16.6 | 0 | 1 | 50 | 2 | 28.6 | |
Other | 11 | 10.6 | 9 | 10.7 | 0 | 0 | 0 | 1 | 50 | 1 | 14.3 | |||
No | 17 | 16.3 | 12 | 14.3 | 21 | 40 | 3 | 50 | 0 | 0 | 11 | 14.3 | ||
Unknown | 6 | 5.8 | 3 | 3.6 | 0 | 0 | 0 | 0 | 3 | 42.9 |